Horizon could have blockbuster in HZN-825 | HZNP Message Board Posts

Horizon Pharma, Inc.

  HZNP website

HZNP   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1874 of 1893  at  7/11/2020 7:32:37 PM  by

drugfree


Horizon could have blockbuster in HZN-825

"Horizon could have blockbuster in HZN-825, says Jefferies 06/29:
HZNP Jefferies analyst David Steinberg noted Horizon Therapeutics recently acquired Curzion for a Phase 2 asset, now called HZN-825, that is targeting diffuse cutaneous systemic sclerosis, or dcSSc, which currently has no FDA approved treatment. While early, HZN-825 has shown encouraging safety and efficacy signals in trials, said Steinberg, who estimates peak sales for the drug of $540M, or $1.4B in peak sales in an upside scenario if the drug is "truly disease modifying." The analyst, who has not included '825 in his model without confirmatory Phase 2 data and notes that '825 is not in street estimates yet either, has a Buy rating and $63 price target on Horizon shares."

FWIW.



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 115
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
1875 Re: Horizon could have blockbuster in HZN-825 geringerart 0 7/13/2020 11:58:54 AM






Financial Market Data provided by
.


Loading...